Floatz logo

Fulranumab

Osteoarthritis, Knee

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.monoclonal_antibodyPhase 2Dormant
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
89/ 100

Competitive context

31 Active assets in the Osteoarthritis, Knee cohort.

Asset / SponsorPhaseRating
Duloxetine
Orthopaedic Arthroscopy Knee and Shoulder Clinic
Phase 4BBB
Naproxen
Pfizer
Phase 3BB
Remimazolam
Seoul National University Hospital
Phase 4BB
Dextrose Solution
Kastamonu University
Phase 4BB
Oxycodone
Riku Antero Palanne
Phase 3BB

View all 48 →

Same molecule, other indications

Fulranumab is also rated in:

radiculopathyDormant
C
Indicative · Phase 2
35 / 100
View asset →
complex regional pain syndrome type 2Dormant
C
Indicative · Phase 2
35 / 100
View asset →
osteoarthritisDormant
C
Indicative · Phase 2
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →